5 completed, 4 not yet recruiting, 4 recruiting, 4 unknown. 14 Phase 2, 8 Phase 1, 3 Phase 3, 2 Not applicable.
Follow this condition Literature Review of Myeloid Malignancies trials Research Report on Myeloid Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 22 | 2026-10-01 | 2026-10-13 |
| Exercise Intervention to Support Recovery After Allogeneic Stem Cell Transplantation in Adults With Myeloid Blood Disorders Multimodal Exercise Intervention - Myeloid Malignancies | Not applicable | Not yet recruiting | Universität Duisburg-Essen | 80 | 2026-10-01 | 2026-10-15 |
| Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan - Venentoclax, Myeloid Malignancies | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 186 | 2026-03-01 | 2026-03-17 |
| A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies Dexamethasone, Cyclophosphamide, Fludarabine - Myeloid Malignancies | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2025-09-03 | 2026-09-04 |
| VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT Venetoclax (VEN), Decitabine (DAC), Busulfan (Bu) - Older Patients, Myeloid Malignancies | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 160 | 2025-07-15 | 2025-07-04 |
| Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies CD33/CD123/CLL-1 CAR-T Cells - Myeloid Malignancies, CAR-T | Phase 1 / Phase 2 | Not yet recruiting | Tongji Hospital | 45 | 2025-04-01 | 2025-04-08 |
| A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies Olutasidenib - Myeloid Malignancies | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 31 | 2024-12-31 | 2026-10-05 |
| MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies Genetic Blood Test - Myeloid Malignancy, Myeloid Malignancies | Not applicable | Withdrawn | Dana-Farber Cancer Institute | 2024-07-29 | 2024-11-22 | |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies Cyclophosphamide, Fludarabine phosphate, Decitabine - Lymphodepleting Chemotherapy, Myeloid Malignancies | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 44 | 2024-06-26 | 2026-09-09 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors KT-253 - Myeloid Malignancies, Acute Lymphocytic Leukemia | Phase 1 | Completed | Kymera Therapeutics, Inc. | 52 | 2023-05-15 | 2025-01-27 |
| A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies Decitabine, Filgrastim - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Active not recruiting | Franziska Wachter | 29 | 2023-04-19 | 2026-08-20 |
| Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies fractionated busulfan-based conditioning regimen - Myeloid Malignancies | Phase 2 | Unknown | Sichuan University | 18 | 2023-03-16 | 2023-04-11 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies Cyclophosphamide, Mesna, Filgrastim - Myeloid Malignancies, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2022-04-08 | 2025-12-19 |
| Study of Magrolimab Combinations in Participants With Myeloid Malignancies Magrolimab, Azacitidine, Venetoclax - Myeloid Malignancies | Phase 2 | Terminated | Gilead Sciences | 54 | 2021-06-28 | 2025-03-20 |
| Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies GvHD prophylaxis - Myeloid Malignancies | Phase 2 | Completed | Gruppo Italiano Trapianto di Midollo Osseo | 78 | 2020-01-15 | 2023-03-10 |
| A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies Anti-LeY-CAR-transduced T cells - Myeloid Malignancies | Phase 1 / Phase 2 | Unknown | Southwest Hospital, China | 45 | 2016-10-01 | 2018-01-23 |
| A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies Anti-CD33-CAR-transduced T cells - Myeloid Malignancies | Phase 1 / Phase 2 | Unknown | Southwest Hospital, China | 45 | 2016-10-01 | 2019-06-25 |
| Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001 - Myeloid Malignancies, Lymphoid Malignancies | Phase 2 | Unknown | Cristina Gasparetto | 36 | 2016-06-08 | 2024-02-20 |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis Imetelstat - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Geron Corporation | 80 | 2012-10-29 | 2021-09-21 |
Showing 20 of 21. Sign in to see all of them.
Myelodysplastic Syndromes (6) · Leukemia, Myeloid, Acute (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Hematologic Neoplasms (2) · Myeloproliferative Disorders (2) · Congenital Bone Marrow Failure Syndromes (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Neoplasms (7) · Bone Marrow Diseases (6) · Leukemia (6) · Neoplasms by Histologic Type (6) · Leukemia, Myeloid (5) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2)
fludarabine (5) · Decitabine (4) · venetoclax (4) · Cyclophosphamide (3) · fludarabine phosphate (3) · Busulfan (2) · Dexamethasone (2) · Filgrastim (2) · Melphalan (2) · Whole-Body Irradiation (2) · Azacitidine (1) · Calcium Dobesilate (1) · Cytarabine (1) · Etoposide (1) · GRN163L peptide (1)
M.D. Anderson Cancer Center (4) · Southwest Hospital, China (2) · Cristina Gasparetto (1) · Dana-Farber Cancer Institute (1) · First Affiliated Hospital of Zhejiang University (1) · Franziska Wachter (1) · Geron Corporation (1) · Gilead Sciences (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Hackensack Meridian Health (1) · Kymera Therapeutics, Inc. (1) · Nanfang Hospital, Southern Medical University (1) · Prelude Therapeutics Incorporated (1) · Sichuan University (1) · Tongji Hospital (1)
United States (12) · China (5) · Australia (2) · Germany (2) · Italy (2) · United Kingdom (2) · Canada (1) · France (1) · Poland (1) · South Korea (1) · Switzerland (1)
Jeremy Ramdial, MD (3) · Cheng Qian, MD, PhD (2) · Annamaria Raiola, MD (1) · Ashwin Gollerkeri, MD (1) · Christopher Reilly, MD (1) · Cristina Gasparetto, MD (1) · Franziska Wachter, MD (1) · Hongtau Liu, MD, PhD (1) · Michele Donato, MD (1) · Miriam Goette, PD Dr. rer. medic. (1) · Nicholas Short, MD (1) · Qifa Liu (1)